EMA Advances Use Of Real-World Data By HTAs And Payers

 
• By Vibha Sharma

Results from the first pilot real-world evidence study commissioned by the European Medicines Agency to help HTA bodies and payers characterize patients with multiple myeloma have drawn positive feedback.

Hand holding global network connection on healthcare, telemedicine, wearable devices, health informatics, digital health, technology and futuristic innovations.
The EMA is using RWD to help a diverse range of decision-makers across the medicinal product’s life cycle • Source: Shutterstock

More from Real-World Evidence

More from Clinical Trials